|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2017
vol. 119 abstract:
Original paper
Aflibercept therapy in diabetic macular oedema – own experience
Anna Michalska
1
,
Martyna Piotrowska
1
,
Mariola Dorecka
2
,
Paweł Stala
1
,
Joanna Miniewicz
3
,
Przemysław Kliś
1
Online publish date: 2018/06/05
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Purpose
The aim of our study was to evaluate the outcomes of intravitreal aflibercept injections in patients with diabetic macular edema. Material and methods Twenty-five patients (15 men, 10 women) aged 45–65 (mean 57) with diabetes mellitus type 2 (28 eyes with diabetic macular edema) were analysed retrospectively. The mean duration of diabetes was 13.5 years. All patients were treated with insulin, oral antidiabetic drugs were additionally used in 8 cases. All patients (28 eyes) received 5 intravitreal injections of aflibercept (2.0 mg) at one month interval. The best corrected visual acuity and mean central retinal thickness (3D OCT 2000 Topcon) were evaluated at baseline and at the end of treatment. The follow up was 6 months. Results There was a significant improvement of best corrected visual acuity and central retinal thickness in the study group of 25 patients. Conclusion Intravitreal injections of aflibercept offer an improvement in visual acuity and central retinal anatomy in patients with diabetic macular edema. keywords:
diabetic macular edema (DME), intravitreal injection of aflibercept, anti-vascular endothelial growth factor (anti-VEGF), central retinal thickness (CRT), optical coherence tomography (OCT) |
|
POLSKI
